Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4683540 | 0.86 | F10 (0.41) | F10MCHR1FPR2 | |
| SCHEMBL6983572 | 0.85 | F10 (0.48) | F10MCHR1CHRM3MGLLPAX8 | |
| SCHEMBL4679663 | 0.75 | F10 (0.73) | F10FPR2 | |
| SCHEMBL4686315 | 0.74 | F10 (0.45) | F10MCHR1MGLLFPR2CHRM4 | |
| SCHEMBL6988835 | 0.71 | F10 (0.47) | F10MCHR1FPR2 | |
| SCHEMBL7091175 | 0.69 | F10 (0.46) | F10MCHR1FPR2 | |
| SCHEMBL4680777 | 0.69 | ROCK2 (0.40) | F10FPR2 | |
| SCHEMBL6984323 | 0.68 | F10 (0.48) | F10FPR2SLC6A9 | |
| SCHEMBL6984298 | 0.65 | F10 (0.51) | F10MCHR1FPR2 | |
| SCHEMBL4680125 | 0.65 | F10 (0.44) | F10MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | claimed |
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | claimed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | claimed |
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | claimed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | claimed |
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | F10 9/4885MCHR1 2420/4885CHRM3 4083/4885 |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | F10 9/4885MCHR1 2420/4885CHRM3 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.